Skip to main content

ORIGINAL RESEARCH article

Front. Neurol.
Sec. Epilepsy
Volume 15 - 2024 | doi: 10.3389/fneur.2024.1429964

Long-term Phenobarbital Treatment is Effective in Working-age Patients with Epilepsy in Rural Northeast China: A 10-year Follow-up Study

Provisionally accepted
Rongxin Li Rongxin Li Danyang Zhao Danyang Zhao Nan Li Nan Li Weihong Lin Weihong Lin *
  • Department of Neurology, First Affiliated Hospital of Jilin University, Changchun, Jilin Province, China

The final, formatted version of the article will be published soon.

    Introduction: Effective management of epilepsy in working-age patients is essential to reduce the burden on individuals, families, and communities. This study aimed to assess the long-term efficacy of phenobarbital (PB) in working-age patients with epilepsy in rural Northeast China and identify the risk factors for seizures during treatment. Methods: Patients aged 18-65 years diagnosed with convulsive epilepsy in rural areas of Jilin Province between 2010 and 2024 were included, and demographic and clinical data were recorded. Seizure frequency, self-efficacy, adherence, and adverse events (AEs) were assessed monthly. Results: Of the 3,568 participants, 288 (8.1%) withdrew from the study and 159 (4.5%) died. During the first year of treatment, 75.2% of patients experienced a ≥50% reduction in seizure frequency compared with baseline (considered as treatment effectiveness); 53.7% of patients were seizure-free. By the tenth year, 97.7% of patients showed treatment effectiveness, and 89.6% were seizure-free. Self-efficacy was improved in 37.8% of patients in the first year and in 72% of patients by the tenth year. The independent risk factors for seizures during treatment were higher baseline seizure frequency (odds ratio [OR]=1.431, 95% confidence interval [CI]: 1.122-1.824), presence of multiple seizure types (OR=1.367, 95% CI: 1.023-1.826), and poor adherence (OR=14.806, 95% CI: 3.495-62.725), with significant differences observed in the first, third, and fifth years. The most commonly reported AEs were drowsiness (43.3%), dizziness (25.0%), and headaches (17.0%), most of which were mild and decreased over time. Age at enrollment was the only factor influencing withdrawal (hazard ratio=0.984, 95% CI: 0.973-0.996, p=0.010), with a substantial number of patients who withdrew (32.6%) relocating for work. Cardiovascular disease was the primary cause of death, and age at enrollment was the only risk factor (hazard ratio=1.026, 95% CI: 1.009-1.043, p=0.002). Discussion: Working-age adults with epilepsy demonstrated a favorable response and tolerability to PB monotherapy. Baseline seizure frequency, seizure type, and adherence consistently predicted prognosis throughout the treatment period. Withdrawal was mainly explained by work-related pressures in this age group. Therefore, it is essential to implement interventions that support patient adherence to therapy and maintain stable regimens.

    Keywords: Adult epilepsy, Working-age population, phenobarbital efficacy, Prognostic predictors, Rural Healthcare, adherence

    Received: 09 May 2024; Accepted: 11 Oct 2024.

    Copyright: © 2024 Li, Zhao, Li and Lin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Weihong Lin, Department of Neurology, First Affiliated Hospital of Jilin University, Changchun, 130021, Jilin Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.